Meiji Yasuda Asset Management Co Ltd. Reduces Stock Holdings in Insulet Corporation $PODD

Key Points

• Meiji Yasuda Asset Management Co Ltd. reduced its holdings in Insulet Corporation by 4.5%, owning 18,901 shares worth approximately $4.96 million after selling 896 shares in the 1st quarter.
• Insulet's stock price opened at $349.56 with a market cap of $24.61 billion, and it recently reported earnings per share of $1.17, exceeding analysts' estimates.
• Equities analysts are optimistic about Insulet's future, with ratings upgraded by several firms, including Wolfe Research and Goldman Sachs, leading to a consensus price target of $335.12.

Meiji Yasuda Asset Management Co Ltd. cut its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 4.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,901 shares of the medical instruments supplier's stock after selling 896 shares during the period. Meiji Yasuda Asset Management Co Ltd.'s holdings in Insulet were worth $4,964,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC increased its position in shares of Insulet by 55.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock worth $1,376,000 after purchasing an additional 1,867 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Insulet by 2.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,909 shares of the medical instruments supplier's stock worth $5,228,000 after purchasing an additional 440 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of Insulet by 85.1% in the first quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock worth $236,000 after purchasing an additional 412 shares during the last quarter. QRG Capital Management Inc. increased its position in shares of Insulet by 75.6% in the first quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier's stock worth $533,000 after purchasing an additional 874 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its position in shares of Insulet by 225.4% in the first quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock worth $408,000 after purchasing an additional 1,075 shares during the last quarter.

Insider Activity at Insulet

In other news, SVP Prem Singh sold 687 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This represents a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

PODD has been the topic of several research analyst reports. Royal Bank Of Canada upped their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Morgan Stanley reissued an "overweight" rating on shares of Insulet in a report on Thursday, August 7th. Wells Fargo & Company raised their price objective on Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a report on Friday, August 8th. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Truist Financial began coverage on shares of Insulet in a research report on Monday, June 16th. They set a "buy" rating and a $365.00 price target on the stock. Sixteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $335.12.

Insulet Trading Up 1.1%

Shares of Insulet stock traded up $3.84 on Friday, hitting $341.78. The stock had a trading volume of 472,873 shares, compared to its average volume of 530,837. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a one year low of $225.37 and a one year high of $353.50. The stock has a market cap of $24.06 billion, a price-to-earnings ratio of 103.88, a PEG ratio of 2.81 and a beta of 1.36. The stock's 50-day simple moving average is $311.59 and its two-hundred day simple moving average is $291.99.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. During the same quarter last year, the business earned $0.55 earnings per share. The business's revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.